1. Market Research
  2. > Cognitive Disorders – Pipeline Review, H1 2013

Cognitive Disorders – Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 378 pages

Cognitive Disorders – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Cognitive Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Disorders. Cognitive Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cognitive Disorders.
- A review of the Cognitive Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cognitive Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cognitive Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cognitive Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Cognitive Disorders - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
Introduction 6
Cognitive Disorders Overview 7
Therapeutics Development 8
Cognitive Disorders Therapeutics under Development by Companies 10
Cognitive Disorders Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 20
Mid Clinical Stage Products 21
Early Clinical Stage Products 22
Discovery and Pre-Clinical Stage Products 23
Cognitive Disorders Therapeutics - Products under Development by Companies 24
Cognitive Disorders Therapeutics - Products under Investigation by Universities/Institutes 33
Companies Involved in Cognitive Disorders Therapeutics Development 35
Cognitive Disorders - Therapeutics Assessment 106
Drug Profiles 112
Cognitive Disorders Therapeutics - Drug Profile Updates 304
Cognitive Disorders Therapeutics - Discontinued Products 346
Cognitive Disorders Therapeutics - Dormant Products 348
Cognitive Disorders - Product Development Milestones 355
Appendix 360

List of Tables

Number of Products Under Development for Cognitive Disorders, H1 2013 25
Products under Development for Cognitive Disorders - Comparative Analysis, H1 2013 26
Number of Products under Development by Companies, H1 2013 28
Number of Products under Development by Companies, H1 2013 (Contd..1) 29
Number of Products under Development by Companies, H1 2013 (Contd..2) 30
Number of Products under Development by Companies, H1 2013 (Contd..3) 31
Number of Products under Development by Companies, H1 2013 (Contd..4) 32
Number of Products under Development by Companies, H1 2013 (Contd..5) 33
Number of Products under Investigation by Universities/Institutes, H1 2013 35
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 36
Comparative Analysis by Late Stage Development, H1 2013 37
Comparative Analysis by Mid Clinical Stage Development, H1 2013 38
Comparative Analysis by Early Clinical Stage Development, H1 2013 39
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 40
Products under Development by Companies, H1 2013 41
Products under Development by Companies, H1 2013 (Contd..1) 42
Products under Development by Companies, H1 2013 (Contd..2) 43
Products under Development by Companies, H1 2013 (Contd..3) 44
Products under Development by Companies, H1 2013 (Contd..4) 45
Products under Development by Companies, H1 2013 (Contd..5) 46
Products under Development by Companies, H1 2013 (Contd..6) 47
Products under Development by Companies, H1 2013 (Contd..7) 48
Products under Development by Companies, H1 2013 (Contd..8) 49
Products under Investigation by Universities/Institutes, H1 2013 50
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 51
Bristol-Myers Squibb Company, H1 2013 52
Boehringer Ingelheim GmbH, H1 2013 53
F. Hoffmann-La Roche Ltd., H1 2013 54
Amgen Inc., H1 2013 55
AstraZeneca PLC, H1 2013 56
Athersys, Inc., H1 2013 57
GlaxoSmithKline plc, H1 2013 58
Merck and Co., Inc., H1 2013 59
Avineuro Pharmaceuticals, Inc., H1 2013 60
Sylentis, H1 2013 61
Novartis AG, H1 2013 62
Astellas Pharma Inc., H1 2013 64
Chiesi Farmaceutici SpA, H1 2013 65
Eisai Co., Ltd., H1 2013 66
H Lundbeck A/S, H1 2013 67
Kowa Company, Ltd., H1 2013 68
Laboratoires Pierre Fabre SA, H1 2013 69
Pfizer Inc., H1 2013 70
Teva Pharmaceutical Industries Limited, H1 2013 71
Evotec Aktiengesellschaft, H1 2013 72
Neuralstem, Inc., H1 2013 73
Ligand Pharmaceuticals Incorporated, H1 2013 74
Lupin Limited, H1 2013 75
Bionomics Limited, H1 2013 76
Neuren Pharmaceuticals Limited, H1 2013 77
ProteoTech, Inc., H1 2013 78
WhanIn Pharmaceutical Co., Ltd., H1 2013 79
Theratechnologies Inc., H1 2013 80
Biotie Therapies Corp., H1 2013 81
Allon Therapeutics Inc., H1 2013 82
Suven Life Sciences Ltd., H1 2013 83
MediPost Co., Ltd., H1 2013 84
Newron Pharmaceuticals S.p.A., H1 2013 85
DiaMedica Inc., H1 2013 86
e-Therapeutics plc, H1 2013 87
Mithridion, Inc., H1 2013 88
Oryzon, H1 2013 89
M et P Pharma AG, H1 2013 90
TauRx Therapeutics Ltd, H1 2013 91
Upsher-Smith Laboratories, Inc., H1 2013 92
Celon Pharma Sp. z o.o., H1 2013 93
AGY Therapeutics, Inc., H1 2013 94
IMMD Inc., H1 2013 95
BioArctic Neuroscience AB, H1 2013 96
PsychoGenics, Inc., H1 2013 97
Adamas Pharmaceuticals, Inc., H1 2013 98
QR Pharma, Inc., H1 2013 99
Siena Biotech S.p.A., H1 2013 100
SeneXta Therapeutics SA, H1 2013 101
Intellect Neurosciences, Inc., H1 2013 102
Dart NeuroScience LLC, H1 2013 103
Omeros Corporation, H1 2013 104
Adeona Pharmaceuticals, Inc., H1 2013 105
Intra-Cellular Therapies, Inc., H1 2013 106
Targacept, Inc., H1 2013 107
Sparsha Pharma International Pvt. Ltd., H1 2013 108
Tautatis Incorporated, H1 2013 109
Galenea Corp., H1 2013 110
VIB, H1 2013 111
M's Science Corporation, H1 2013 112
Pharnext SAS, H1 2013 113
Gaia BioPharma Limited, H1 2013 114
Sinil Pharma Ltd., H1 2013 115
Heptares Therapeutics Ltd., H1 2013 116
Pacific Northwest Biotechnology, LLC, H1 2013 117
Pherin Pharmaceuticals, Inc., H1 2013 118
PhysioGenix, Inc., H1 2013 119
BIOPROJET SCR, H1 2013 120
Varinel, Inc., H1 2013 121
Naurex, Inc., H1 2013 122
Assessment by Monotherapy Products, H1 2013 123
Assessment by Combination Products, H1 2013 124
Assessment by Stage and Route of Administration, H1 2013 126
Assessment by Stage and Molecule Type, H1 2013 128
Cognitive Disorders Therapeutics - Drug Profile Updates 321
Cognitive Disorders Therapeutics - Discontinued Products 363
Cognitive Disorders Therapeutics - Discontinued Products (Contd..1) 364
Cognitive Disorders Therapeutics - Dormant Products 365
Cognitive Disorders Therapeutics - Dormant Products (Contd..1) 366
Cognitive Disorders Therapeutics - Dormant Products (Contd..2) 367
Cognitive Disorders Therapeutics - Dormant Products (Contd..3) 368
Cognitive Disorders Therapeutics - Dormant Products (Contd..4) 369
Cognitive Disorders Therapeutics - Dormant Products (Contd..5) 370
Cognitive Disorders Therapeutics - Dormant Products (Contd..6) 371

List of Figures

Number of Products under Development for Cognitive Disorders, H1 2013 25
Products under Development for Cognitive Disorders - Comparative Analysis, H1 2013 26
Products under Development by Companies, H1 2013 27
Products under Investigation by Universities/Institutes, H1 2013 34
Late Stage Products, H1 2013 37
Mid Clinical Stage Products, H1 2013 38
Early Clinical Stage Products, H1 2013 39
Discovery and Pre-Clinical Stage Products, H1 2013 40
Assessment by Monotherapy Products, H1 2013 123
Assessment by Combination Products, H1 2013 124
Assessment by Route of Administration, H1 2013 125
Assessment by Stage and Route of Administration, H1 2013 126
Assessment by Molecule Type, H1 2013 127
Assessment by Stage and Molecule Type, H1 2013 128

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.